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Abstract Chronic heart failure is a major healthcare
problem associated with high morbidity and mortality.
Despite significant progress in treatment strategies, the
prognosis of heart failure patients remains poor. The golden
standard treatment for heart failure is heart transplantation
after failure of medical therapy, surgery and/or cardiac
resynchronisation therapy. In order to improve patients’
outcome and quality of life, new emerging treatment
modalities are currently being investigated, including
mechanical cardiac support devices, of which the left
ventricular assist device is the most promising treatment
option. Structured care for heart failure patients according
to the most recent international heart failure guidelines may
further contribute to optimal decision-making. This article
will review the conventional and novel treatment modalities
of heart failure.
Keywords Heart failure.Surgery.Resynchronization
therapy.Mechanical cardiac support.Heart failure program
Introduction
Chronic heart failure (HF) is a major healthcare problem
associated with high morbidity and mortality. In the
Netherlands, an estimated 180,000 patients in a population
of 16.5 million suffer from HF with an incidence rate of
35,000 patients per year [1]. Over the last two decades, no
change has been observed in the incidence of HF, despite
better prevention and treatment options [2]. Notwithstand-
ing significant progress in treatment modalities, the prog-
nosis of HF patients still remains poor. It was demonstrated
that patients with drug refractory end-stage HF receiving
support with inotropic drugs had a 3-, 6-, and 12-month
survival of 51%, 26%, and 6%, respectively, with a mean
survival of only 3.4 months [3]. For these patients, heart
transplantation (HTX) remains the only option [4, 5]. In
comparison with conventional treatment, HTX significantly
provides a better quality of life and increases survival: it
is associated with a 90% 1-year and a 80% 3-year
survival [6].
Nevertheless, only a fraction of the HTX candidates will
actually benefit from transplantation, as the number of
available donor hearts is limited. Moreover, strict selection
criteria result in the exclusion of many candidates.
However, new surgical techniques, cardiac resynchroni-
sation therapy (CRT), and mechanical cardiac support may
emerge as promising options for this patient group. Because
of the large number of treatment options, it is important that
before treatment, HF patients should always enter a
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HF program, to determine the aetiology of HF and to
identify possible treatment options.
Pharmacological therapy and lifestyle changes
The aim of HF treatment is to prevent progression of
symptoms and to improve survival. Treatment of HF is
based on two cornerstones: lifestyle intervention and
pharmacological therapy. Lifestyle changes include restric-
tion of sodium and fluid intake, losing weight, cessation of
smoking and alcohol, and participation in a rehabilitation
program [4]. Besides optimal control of risk factors (e.g.
hypertension, coronary artery disease, and diabetes mellitus),
drugtreatmentofHFincludesangiotensin-convertingenzyme
(ACE) inhibitors or, when not tolerated, angiotensin II
receptorblockers.Furthermore,diuretics,aldosteronereceptor
antagonists, digoxin, and beta-blockers are important in the
pharmacological treatment of HF. In the past decades,
several large clinical randomised trials have demonstrated
the value of these drugs in reduction of mortality,
improvement of functional status, and reduction of the
number of hospitalisations [4].
Surgical treatment
In addition to pharmacological therapy, novel surgical
techniques to alleviate HF have been introduced. These
surgical techniques address different pathophysiological
mechanisms in HF. Revascularisation may potentially
improve the outcome of patients with ischaemic cardiomy-
opathy. Despite the significant periprocedural risk of
morbidityandmortality,severalstudiesdemonstratedahigher
survival rate and improved New York Heart Association
(NYHA) functional class in patients with HF after coronary
artery bypass grafting (CABG) compared with patients on
optimal medical therapy only [7, 8].
In patients with ischaemic cardiomyopathy, LV remodel-
ling, characterised by an increase in LV volume and a
deteriorating cardiac function, is associated with progression
of HF and poor prognosis [9]. Surgical ventricular restoration
(SVR) aims to correct ventricular remodelling by restoring
LV geometry and reducing its volume, thus improving LV
function (Fig. 1)[ 10, 11]. The RESTORE study examined
early and late outcome after SVR in 1,198 postinfarction
patients. In this study, there was an improvement of
approximately 10% in LV ejection fraction and all patients
had a decrease in symptoms. After surgery, 30-day mortality
was 5.3% and overall 5-year survival was 68.6% [12]. In the
STICH trial, 1,000 patients with an LV ejection fraction
<35% were randomly assigned to CABG in combination
with SVR or CABG alone [13]. Primary endpoints were
death and hospitalisation for cardiac causes. A significant
reduction (19%) of the end-systolic volume index was found
in the SVR group compared with a 6% reduction in the
CABG group. However, no difference in reduction of cardiac
symptoms or improvement of exercise tolerance was ob-
served. Furthermore, SVR did not reduce the rate of death or
hospitalisation for cardiac causes compared with CABG
alone.
Another surgical intervention that addresses ventricular
remodelling is the implantation of a CorCap Cardiac
Support Device (CSD; Acorn Cardiovascular Inc, St. Paul,
MN, US). The CorCap CSD is a passive external fabric
mesh containment device that is surgically implanted
around the heart in order to reduce LV wall stress by
providing circumferential diastolic support. In the Acorn
trial, the safety and efficacy of the CorCap CSD was
assessed in 300 NYHA class III-IV HF patients. Patients
were excluded if there was a need for other cardiac surgical
procedures than mitral valve replacement. The use of the
CorCap CSD resulted in a significant decrease of LV
volumes and LV sphericity and improved functional status
and quality of life [14]. During 3 years of follow-up, these
changes were maintained, demonstrating the long-term
beneficial effect of the CorCap CSD on reverse remodelling
in HF patients [15].
Functional mitral regurgitation (MR) frequently develops
in patients with chronic HF. In 2,057 HF patients from the
Duke Cardiovascular Databank, MR of any grade was
present in almost 60% [16]. In HF patients, functional MR
develops because of LV dilatation and deformation, which
leads to incomplete leaflet coaptation. The development of
MR is associated with worsening of symptoms and
decreased survival [16]. Conservative management of
severe to moderate functional MR was associated with a
5-year survival of approximately 40%, independent of the
aetiology, compared with a 5-year survival rate of 55% in
HF patients without MR [16]. Mitral valve surgery aims to
treat MR by undersizing the mitral annulus by a restrictive
mitral annuloplasty (RMA). In a study of 51 patients with
ischaemic LV dysfunction and severe MR, combined RMA
and CABG led to reduced LV remodelling and symptoms
and a 2-year survival of 84% [17]. However, despite these
promising data, no large randomised controlled trials have
been performed to address the long-term outcome of this
procedure as compared with other therapeutic options.
Cardiac resynchronisation therapy (CRT)
An important development has been the implementation of
CRT. In approximately 25% of patients with HF, intraven-
tricular conduction delay is apparent [18], resulting in
168 Neth Heart J (2012) 20:167–175asynchronous ventricular contraction. Asynchrony may
further reduce systolic function and cardiac output in the
already challenged heart [19]. In this light, CRT (first
introduced by Dr. Bakker from Utrecht, the Netherlands)
has emerged as a well-established therapy for patients with
advanced HF. Cardiac stimulation resynchronises ventricu-
lar contraction thereby improving LV systolic function.
Current indications for CRT are NYHA functional class III
toIV,LVejectionfraction<35%,andaQRSduration>120ms
[4]. Two large randomised clinical trials, MADIT-CRT [20]
and REVERSE [21], evaluated CRT in mild to moderate HF
patients and demonstrated significant reverse remodelling
and a significant reduction in HF events. Based on this, the
guidelines also recommended CRT in patients with NYHA
Fig. 1 Surgical restoration of the left ventricle which aims to restore
ventricular remodelling by reshaping left ventricular geometry and
reducing its volume. This results in an improvement in the function of
the left ventricle. Figures A to E demonstrate the consecutive steps of
this procedure (Reprinted with permission of Eisen) [11]
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demonstrated on symptoms of HF, functional capacity and
quality of life [23]. Furthermore, CRT significantly reduces
mortality and hospitalisation rate due to HF [24]. However,
one third of the patient population with CRT does not show
response in terms of reverse LV remodelling and clinical
improvement [25].
Despitethecurrentestablishedtreatmentoptions,including
drugs, surgery and CRT, a significant number of patients will
experience deteriorating symptoms and eventually die. There-
fore,itishopefulthatmechanicalcardiacsupport,apromising
innovative treatment option, may improve the outcome of
these patients.
Mechanical cardiac support
In 1966, the first ventricular assist device (VAD) was
implanted by DeBakey as bridge to recovery. This was
the beginning of mechanical circulatory support for
advanced HF.
VADs are mechanical circulatory pumps which partially
or completely take over ventricular function in order to
assist the circulation and improve end-organ perfusion. A
VAD can be used as an LV (LVAD), right ventricular
(RVAD), and as biventricular assist device (BiVAD).
Mechanical circulatory support is used for three indications
[26]. (1) As bridge to HTX, in which a patient receives a
VAD for a relatively short time in order to survive the
waiting list period until transplantation and to prevent
further deterioration and even improve secondary organ
function. (2) As bridge to recovery, in which the device
is implanted in order to allow the heart to recover in,
for example, patients with post-cardiotomy shock or
peripartum cardiomyopathy. Patients are expected to
fully recover and mechanical circulatory support is
usually short term. (3) As destination therapy, when
recovery cannot be expected and the patient is not a
candidate for HTX. Especially with the new-generation
of devices, VAD therapy may become an important
treatment modality on top of optimal medical therapy,
surgery and/or CRT.
The first generation of assist devices were large para-
corporal pulsatile devices. These pumps could be used in
both ventricles. The large pump chamber was placed on the
abdominal wall of the patient and connected by conduits
to the great arteries. Besides numerous complications due
to the size of the devices, patients were bedridden [26,
27]. Miniaturisation of the control and power-supply
components and technological advances resulted in
smaller wearable pulsatile VADs that were implanted
intra-abdominally. These pumps were either pneumatically
or electrically driven [26, 27]. Because of their smaller
implantable size, patients could mobilise, rehabilitate and
even leave the hospital [28]. However, because of the
large volume of the pump only patients with a body
surface area >1.5 m
2 were able to receive these mechanical
assist devices. Moreover, extensive surgery was necessary
because of the size, increasing the risk of haematomas and
infection [29]. Due to multiple moving parts the devices
were prone to fail and could only be used for a limited
amount of time. Anticoagulation was required except for
the HeartMate XVE.
The second-generation assist devices consist of smaller
axial continuous flow pumps (Fig. 2). Therefore, they
require less extensive surgery reducing the risk of peri-
operative complications. Because these devices contain
only one moving part they are more durable than pulsatile
devices and noiseless [27, 30]. During development of the
continuous flow pump, there was concern that continuous
flow and therefore continuous end-organ perfusion could
not be tolerated by the body. This has been contradicted by
demonstrating superior survival and less organ failure in
patients with continuous flow VADs compared with
patients with pulsatile VADs [30].
Further development led to the third-generation devices
consisting of even smaller centrifugal blood pumps (Fig. 3a
and b). These pumps have magnetically levitated rotors
preventing mechanical wear (Fig. 4). Therefore, it is
expected that durability is significantly improved compared
with older devices. Because of the small size, the pumps can
be implanted intrapericardially further reducing postoperative
complications. The first report on the clinical use of the
HeartWare ventricular assist device (HVAD) pump (Heart-
Ware Inc, Framingham, MA), a third-generation device,
showed in 23 patients promising results with a 6-month and
1-year survival of 91% and 86%, respectively [31]. Infection
and bleeding were found to be the most common adverse
events. Another multicentre trial using a third-generation
VentrAssist LVAD (Ventracor Ltd, Chatswood, NSW, Aus-
tralia) in 33 patients demonstrated a favourable efficacy and
safety profile for the use of this device as bridge to transplant
[32]. After a median support time of 142 days, 82% of the
patients were either transplanted or remained eligible for
transplant. Major adverse events were infections, non-
neurological thromboembolic events, neurological events,
and haemorrhages. There was a significant improvement in
quality of life and 81% of the patients achieved NYHA class
I or II at the end of the trial [32].
Bridge to HTX
Since the introduction of LVAD therapy as bridge to
transplant in the 1980s, this concept has been evaluated in
several studies. One multicentre clinical trial reported a
65% survival until transplantation of 34 patients who
170 Neth Heart J (2012) 20:167–175received a LVAD as compared with 50% in 6 patients who
were treated with medication only [33]. Similar results were
reported with survival until HTX of 60–75% [34]. All
studies were performed with first-generation pulsatile
devices. Although it was demonstrated that haemodynamics
and quality of life improved [34], a high adverse event rate
was frequently reported.
With the development of the continuous flow assist
devices, some of the constraints of the pulsatile devices
improved, such as the high device failure rate and
associated morbidity. In a multicentre study, 133 NYHA
class IV patients received a HeartMate II device as bridge
to transplant [35]. Overall survival was 75% at 6 months
and 68% at 12 months. In this study, major adverse events
Fig. 2 Panel A shows a first-generation pulsatile flow left ventricular
assist device (LVAD). Panel B shows a second-generation continuous
flow LVAD. Both mechanical pumps are placed in the abdominal wall.
The inflow cannula is placed in the apex of the left ventricle. The
outflow cannula is anastamosed with the ascending aorta. A
percutaneous lead connects the LVAD pump with an external system
controller and the battery pack (Reprinted with permission of
Slaughter et al.) [30]
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neous lead infection. Five devices were replaced due to
pump thrombosis or complications related to surgical
implantation.
Bridge to recovery
In a small number of patients, it has been reported that an
LVAD could be explanted because of recovery of myocar-
dial function, allowing the patient to be removed from the
waiting list for HTX as well [36]. The general idea of
cardiac recovery after LVAD implantation is that unloading
of the ventricle leads to reverse remodelling on genetic,
molecular and functional levels [37]. The reported frequency
varies from 5% to 29% [37, 38]. Recovery of myocardial
function seems to be more likely in patients with myocarditis
or non-ischaemic cardiomyopathy, e.g. peripartum cardio-
myopathy [38, 39]. However, rapid LV dysfunction after
removal of the assist device has been reported [37]. There
are no reliable parameters to predict outcome after explan-
tation, nor is there at present a way to predict, before
implantation, in which patients cardiac function will recover.
Destination therapy
Currently, LVADs are implanted as bridge to transplant in
most patients. However, since the waiting time on the list
for HTX only increases in most Western countries, duration
of mechanical support becomes longer. Moreover, some
patients who received a LVAD as bridge to transplant
removed themselves from the waiting list and continued
being on mechanical cardiac support. Therefore, the
question is legitimate if it is feasible to use LVADs as
destination therapy [40].
In the Randomized Evaluation of Mechanical Assistance
for the Treatment of Congestive HF (REMATCH) trial, the
feasibility of LVAD therapy as destination therapy was
evaluated in 129 patients with end-stage HF who were
randomly assigned to receive either optimal medical
treatment or LVAD therapy on top of optimal medical
therapy [41]. HTX was contraindicated in all patients. A
48% risk reduction of death from any cause was demon-
strated in the LVAD group. Additionally, functional
capacity and quality of life were significantly better in the
device group compared with the group on optimal medical
therapy only. Despite these positive results, serious com-
plications occurred 2.35 times more often in the device
group than in the medically treated group. The second
study evaluating VADs in non-transplantable patients was
the Investigation of Nontransplant-Eligible Patients Who
Fig. 4 HeartWare left ventricular assist device pump. The pump has
one moving part, the impeller. There are no mechanical bearings
(Reproduced with permission of HeartWare Inc.)
Fig. 3 Third-generation HeartWare ventricular assist device (HVAD).
This device consists of a magnetically levitated rotor pump that
prevents mechanical wear. The pump is implanted in the pericardial
space in the apex of the left ventricle. The outflow graft is connected
with the ascending aorta. The controller and external batteries are
connected to the pump by a percutaneous driveline. In panel A, a chest
x-ray is shown of a patient with a HVAD implant and an internal
cardioverter defibrillator. Panel B shows the position of all the
components of the HVAD system (Panel B reproduced with
permission of HeartWare Inc.)
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randomised trial reinforced the results of the REMATCH
trial by demonstrating significantly better survival and
improvement of symptoms and quality of live in patients
with a VAD compared with patients on optimal medical
treatment only. However, this study also reported that
LVAD implantation resulted in an increased risk of
neurological events, infections, and bleeding complications
as compared with a medically treated control group of
patients [42]. The first randomised trial comparing first-
generation pulsatile VADs (HeartMate XVE) with second-
generation continuous flow devices (HeartMate II) in a 1:2
ratio including 200 patients as destination therapy was
recently published [30]. The 2-year survival free from
disabling stroke, and reoperation to repair or replace LVAD
for the continuous group was 46% compared with 11% for
the pulsatile flow group. Reoperation for pump replacement
of the continuous flow LVAD occurred at a rate of 6 events
per 100 patient-years, mostly because of damage to the
percutaneous lead. No difference in the occurrence of
stroke between the two devices was observed. The 1-year
actuarial survival rates were 68% and 55% for the
continuous flow and pulsatile flow group, respectively,
and the 2-year survival rates 58% and 24%, respectively.
Both devices improved NYHA functional class and quality
of life as compared with baseline characteristics. The
continuous flow assist device was associated with a
significant reduction in adverse events as compared with
the pulsatile assist device. The HeartMate II received Food
and Drug Administration approval as destination therapy in
2010.
Since the first implant in 1966, mechanical cardiac
support has undergone continuous development. With each
new adjustment, the constraints of VADs become less. The
longevity of the new devices is expected to be superior to
the older devices. Still, there is concern about the risk of
adverse events, including bleeding complications and
thromboembolic events. More experience in management
of these devices may result in fewer complications and
better survival.
Fig. 5 Comprised flow chart of the MISSION! Heart failure protocol at the Leiden University Medical Centre
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HF is a complex syndrome with a large variety of
aetiologies and treatment options, which ranges from
pharmaceutical treatment to mechanical support. Not every
patient is eligible for all treatment modalities and patients
who receive treatment do not always benefit or respond in
the desired manner. Therefore, structured screening and
treatment procedures embedded within a dedicated and
comprehensive HF program are mandatory.
The Leiden MISSION! HF program, initiated in 2005, is
an example of such a program (Supplementary Fig. 1). This
protocol aims to assess and treat patients according to the
most recent guidelines of the European Society of Cardi-
ology for HF [4, 22] and allows implementation of new
treatment modalities in order to improve patient care and
survival. MISSION! HF is a multidisciplinary approach
program with participation of all the care professionals
involved.
To achieve an efficient and accurate treatment strategy
per patient, patients referred to the MISSION! HF outpa-
tient clinic are extensively screened. This screening
program consists of clinical and functional evaluations,
including two- and three-dimensional echocardiography,
nuclear imaging, MIBG scanning, coronary angiography,
and 24-hour ambulatory ECG Holter monitoring.
Guided by the results of the screening program, patients
receive tailored treatment according to current guidelines [4,
22]. The treatment includes focus on lifestyle changes,
optimal medical treatment and rehabilitation and is led by a
specialised HF nurse. Furthermore, in every patient, it is
important to question the possibility of revascularisation,
valve repair, SVR or implantation of a CorCap. Also, the
risk of sudden death is evaluated. Patients who are not
eligible for conventional treatment are considered candidates
for more advanced treatment options, such as HTX, cell
therapy or LVAD support (Fig. 5 and Supplementary Fig. 1).
After screening and start of treatment, patients are
followed at the outpatient clinic on a regular basis. During
these visits, functional status and treatment is evaluated in a
structured manner.
Conclusion
Progressive symptoms of HF are devastating for both
patients and partners. Currently, after failure of medical
therapy, surgery and/or CRT, HTX is still the gold
standard treatment modality. New treatment options,
including mechanical support devices, are under inves-
tigation. In patients with end-stage HF, LVAD therapy is
currently the most promising treatment option and with
the miniaturisation of the devices, it can be expected
that the number of implants will rise significantly. In
this context, it remains indispensible to individualise
patients’ treatment strategies.
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